Epigenetics in Cancer

Dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible, and thus make a promising therapeutic target.

Epigenetics in Cancer Products Targets

Products for Epigenetics in Cancer

Cat.No. Product Name Information/Activity
BCC2383 R18 Inhibitor of 14.3.3 proteins
BCC2188 CCT137690 CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively.
BCC2174 Hesperadin Hesperadin is an ATP-competitive inhibitor of aurora B kinase with an IC50 of 250 nM.
BCC2184 PF-03814735 PF-03814735 is a potent, orally available and reversible aurora A and aurora B inhibitor with IC50s of 0.8 and 0.5 nM, respectively.
BCC2177 SNS-314 Mesylate SNS-314 is a potent and selective aurora kinase inhibitor with IC50s of 9, 31, and 6 nM for aurora A, B and C, respectively.
BCC2418 TC-A 2317 hydrochloride Potent, selective Aurora kinase A inhibitor
BCC2182 Aurora A Inhibitor I Potent and selective Aurora kinase A inhibitor,Aurora A Inhibitor I is a novel, potent, and selective inhibitor of Aurora A with IC50 of 3.4 nM in a cell-free assay. It is 1000-fold more selective for Aurora A than Aurora B.
BCC2167 VX-680 (MK-0457,Tozasertib) Tozasertib (VX 680; MK-0457) is an inhibitor of Aurora A/B/C kinases with Kis of 0.6, 18, 4.6 nM, respectively.
BCC2169 ZM 447439 ZM-447439 is an aurora kinase inhibitor with IC50s of 110 and 130 nM for aurora A and B, respectively.
BCN2483 Ginkgolic acid C15:0 Anacardic Acid, extracted from cashew nut shell liquid, is a histone acetyltransferase inhibitor, inhibits HAT activity of p300 and PCAF, with IC50s of ∼8.5 μM and ∼5 μM, respectively.